Esperion Therapeutics Inc
ESPRLatest QuantConomy context for ESPR: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.
Esperion Therapeutics Inc
Esperion Therapeutics Inc (ESPR) is a publicly traded American pharmaceutical company headquartered in Ann Arbor, Michigan. The company is dedicated to developing and commercializing innovative, oral therapies to reduce cardiovascular risk, particularly by lowering elevated levels of low-density lipoprotein cholesterol (LDL-C). Its primary products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which are designed to address the needs of patients with hypercholesterolemia who are inadequately treated with current lipid-modifying therapies. Founded by Dr. Roger S. Newton in 2008, Esperion focuses on delivering targeted mechanisms of action to address unmet medical needs in the cardiovascular space.
- Symbol
- ESPR
- Name
- Esperion Therapeutics Inc
- Coverage
- 3 market/data records
- Sources
- alphavantage alpaca fmp sec nasdaq openfigi
Recent signals for ESPR
Scored rows are pulled from the same signal API used by the digests.
| Signal | Direction | Score | Observed | Reason |
|---|---|---|---|---|
| eps change | very bullish | 95 | Jul 11, 12:00 AM | ESPR (Q1 2026, diluted eps): EPS grew 52.4% ($-0.21 → $-0.10). [year-over-year basis, very bullish signal] |
| net income change | bullish | 87 | Jul 11, 12:00 AM | ESPR (Q1 2026, net income): grew 37.7% (-$40.45M → -$25.20M). [year-over-year basis, bullish signal] |
| revenue change | very bearish | 76 | Jul 11, 12:00 AM | ESPR (Q1 2026, revenue): declined 72.8% ($159.57M → $43.39M). [sequential period basis, very bearish signal] |
FUNDAMENTAL signals are experimental: the generator was recently enabled and coverage is still being validated.
Market coverage
| Market | Exchange | Source | Asset record |
|---|---|---|---|
| ESPR | NASDAQ | alphavantage | Esperion Therapeutics Inc |
| ESPR | NASDAQ | alpaca | Esperion Therapeutics, Inc. Common Stock |
| ESPR | NASDAQ | fmp | Esperion Therapeutics, Inc. |
Recent insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Halladay Benjamin | Chief Financial Officer | sale | 10,773 | $3.16 | $33,989 | 4 on EDGAR |
| Jun 17, 2026 | Looker Benjamin | Chief Legal Officer | sale | 11,824 | $3.16 | $37,305 | 4 on EDGAR |
| Jun 17, 2026 | Koenig Sheldon L. | President and CEO | sale | 53,588 | $3.16 | $169,070 | 4 on EDGAR |
| May 28, 2026 | Hoffman Robert E. | Insider | grant | 79,873 | $0.00 | $0 | 4 on EDGAR |
| May 28, 2026 | Fischer Seth H. Z. | Insider | grant | 79,873 | $0.00 | $0 | 4 on EDGAR |
| May 28, 2026 | CARROLL J MARTIN | Insider | grant | 79,873 | $0.00 | $0 | 4 on EDGAR |
| May 28, 2026 | THOMPSON JOHN CRAIG | Insider | grant | 79,873 | $0.00 | $0 | 4 on EDGAR |
| May 28, 2026 | Shepard Jay | Insider | grant | 79,873 | $0.00 | $0 | 4 on EDGAR |
| Mar 17, 2026 | Looker Benjamin | Chief Legal Officer | sale | 5,708 | $2.70 | $15,429 | 4 on EDGAR |
| Mar 17, 2026 | Koenig Sheldon L. | President and CEO | sale | 25,578 | $2.72 | $69,547 | 4 on EDGAR |
| Mar 17, 2026 | Halladay Benjamin | Chief Financial Officer | sale | 6,424 | $2.71 | $17,377 | 4 on EDGAR |
| Mar 13, 2026 | Looker Benjamin | Chief Legal Officer | grant | 300,840 | $0.00 | $0 | 4 on EDGAR |
| Mar 13, 2026 | Koenig Sheldon L. | President and CEO | grant | 723,760 | $0.00 | $0 | 4 on EDGAR |
| Mar 13, 2026 | Halladay Benjamin | Chief Financial Officer | grant | 247,430 | $0.00 | $0 | 4 on EDGAR |
| Jan 20, 2026 | Looker Benjamin | General Counsel | sale | 1,689 | $2.88 | $4,868 | 4 on EDGAR |
| Dec 4, 2025 | Harlow John B. Jr. | Chief Commercial Officer | grant | 424,536 | $0.00 | $0 | 4 on EDGAR |
Source: SEC filings via QuantConomy. Not investment advice.
Query ESPR context like a database.
These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.
More: All insider trades · How to read a Form 4 · API access